Compare RGP & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGP | TLSA |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.4M | 145.1M |
| IPO Year | 2000 | 2017 |
| Metric | RGP | TLSA |
|---|---|---|
| Price | $2.80 | $1.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $5.67 | ★ $8.02 |
| AVG Volume (30 Days) | 406.2K | ★ 582.2K |
| Earning Date | 10-07-2026 | 05-01-2026 |
| Dividend Yield | ★ 9.37% | N/A |
| EPS Growth | ★ 79.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $452,006,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.88 | $0.76 |
| 52 Week High | $5.37 | $2.20 |
| Indicator | RGP | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 19.83 | 60.42 |
| Support Level | N/A | $1.14 |
| Resistance Level | $4.63 | $1.20 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 0.41 | 76.81 |
Resources Connection Inc is a professional services firm. Its segments include On-Demand Talent provides businesses with a go-to source for bringing in experts when its needed, serving the office of the CFO; Consulting drives transformation across people, processes and technology across domain areas including finance, technology and digital, risk and compliance and operational performance; Europe & Asia Pacific offers both on-demand and consulting services to clients throughout Europe and Asia Pacific; Outsourced Services; and Sitrick. It derives the majority of revenue from On-Demand Talent segment. Geographically, it operates in United States and internationally.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.